CJC-1295 with DAC versus no DAC: match the exact form
Resolve CJC-1295 naming before comparing sources. Check the DAC modification, full structure and study material instead of transferring evidence between names.
DAC is a structural detail that must stay attached to a CJC-1295 reference. Do not transfer a result from the long-acting compound to a preparation described as “no DAC” without establishing that the study tested that exact material.
Treat the short name as a starting point
The FDA’s December 2024 compounding briefing lists CJC-1295-related substances with and without DAC, including different salt forms. That distinction is enough to make an unqualified “CJC-1295” label an incomplete basis for matching a source.
The briefing is historical advisory material. It is used here to explain naming distinctions, not to make a statement about a preparation’s current regulatory status or suitability for administration.
Source context: FDA: December 2024 compounding briefing.
Keep the study attached to its compound
The cited Teichman paper reports work on a long-acting CJC-1295 analogue in healthy adults. A familiar name in its title does not make it a study of every catalog item carrying that name. Read the description of the study material before repeating a result.
If a secondary article reports a duration or a hormone response, follow its citation back to the original study. Copy the exact form into your notes. Leave a no-DAC preparation’s corresponding entry unresolved when the source does not test it.
Source context: Teichman et al.: long-acting CJC-1295 in healthy adults.
Build an identity record before a comparison
For each material, collect the full sequence, modifications, terminal groups, DAC status and salt or counterion. Include the laboratory’s identity reference and the observed analytical result. A supplier alias can help you find a record, but it should not replace that record.
Monday keeps the long-acting DAC entry separate from modified GRF (1–29), a name associated with no-DAC preparations. Use the two Atlas records to organize questions, then verify the exact specification against the original documents. Market naming may be inconsistent.
Write a summary that does not transfer evidence
A useful comparison states which source belongs to each column and identifies any unmatched structural detail. If only one form has a relevant study in your reading set, show that gap instead of filling the other column with the same result.
This process can end with an unanswered question. That is a valid research outcome. Ask for the missing identity document before building a more detailed interpretation, and retain the distinction in any research pack you share.
Your reading checklist
- Record DAC status explicitly.
- Check sequence, modifications and salt separately.
- Match each study to the exact material it describes.
- Keep an unsupported no-DAC result blank.
This is a reading aid, not a laboratory certification or a treatment recommendation.
Common questions
Can I reuse the published long-acting study for a no-DAC preparation?
Only if the source actually establishes that it tested the material under discussion. The short name alone is not sufficient.
Is the FDA briefing an approval document?
No. The linked document presents background and proposals for an advisory committee meeting. This article does not use it as a current approval determination.
Sources and scope
Sources checked . Prepared with AI assistance and checked against the cited sources. No independent clinical review is claimed.
- FDA: December 2024 compounding briefing
The briefing identifies separate CJC-1295 forms with and without DAC. It is historical advisory material, not a current approval determination.
- Teichman et al.: long-acting CJC-1295 in healthy adults
A study of the long-acting compound. It does not establish outcomes for a differently specified product.
Read the editorial policy or suggest a correction.
Publication history
- : First publication.